Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Propranolol for infantile hemangioma: Current state of affairs
Andre V Moyakine, Carine JM van der Vleuten, Department of Dermatology, Hecovan Expertise Center for Hemangioma and Vascular Malformations, Radboud University Medical Centre, Nijmegen, 6500 HB Gelderland, The Netherlands
Author contributions: Moyakine AV and van der Vleuten CJM contributed equally to this work; Moyakine AV wrote the majority of the original draft of the paper and approved the final version of this paper; van der Vleuten CJM devised the design of the study and participated in writing the paper; van der Vleuten CJM approved the final version of this paper and guarantees that all individuals who meet the journal’s authorship criteria are included as authors of this paper.
Conflict-of-interest statement: Both authors have no conflicts of interest relevant to this article to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Andre V Moyakine, MD, Department of Dermatology, Hecovan Expertise Centre for Hemangioma and Vascular Malformations, Radboud University Medical Centre, PO box 9101, Nijmegen, 6500 HB Gelderland, The Netherlands. andre.moyakine@radboudumc.nl
Telephone: +31-24-3613724 Fax: +31-24-3541184
Received: August 27, 2015
Peer-review started: August 31, 2015
First decision: September 28, 2015
Revised: October 19, 2015
Accepted: December 13, 2015
Article in press: December 14, 2015
Published online: February 2, 2016
Processing time: 154 Days and 23 Hours
Peer-review started: August 31, 2015
First decision: September 28, 2015
Revised: October 19, 2015
Accepted: December 13, 2015
Article in press: December 14, 2015
Published online: February 2, 2016
Processing time: 154 Days and 23 Hours
Core Tip
Core tip: The discovery that propranolol is efficacious in the treatment of infantile hemangioma (IH) has led to an upsurge in publications, increasing our knowledge of this subject. In this review, we provide the most up-to-date information on the pathophysiology, variations in clinical presentation, and natural history of IH. We look at possible working mechanisms of several treatments and the current concerns regarding the treatment of first choice, propranolol. Finally, we provide an overview of instruments, measuring IH severity and/or activity and IH-related quality of life.